Chiesi SAS clinical trials
Acquired by Chiesi Farmaceutici S.p.A., Jul 28, 2009 · source ↗
The registry lists 4 studies whose lead sponsor is Chiesi SAS. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 13, 2025.
Before and after it joined Chiesi Farmaceutici S.p.A.
- First submitted before Chiesi SAS became part of Chiesi Farmaceutici S.p.A.
- 0
- First submitted after Chiesi SAS became part of Chiesi Farmaceutici S.p.A.
- 4
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Chiesi SAS3 studies
- Chiesi USA, Inc.1 study
Something wrong with this grouping? Tell us on the Chiesi Farmaceutici S.p.A. page.
Studies
Recruiting first, then most recently updated. Showing 4 of 4. All Chiesi Farmaceutici S.p.A. studies →
- Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial IntelligenceNot yet recruitingNCT06960824
Sponsor listed in the registry: Chiesi SAS · First submitted after Chiesi SAS became part of Chiesi Farmaceutici S.p.A.
- Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT StudyRecruitingNCT05948891
Sponsor listed in the registry: Chiesi SAS · First submitted after Chiesi SAS became part of Chiesi Farmaceutici S.p.A.
- A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related OutcomesRecruitingNCT05728749
Sponsor listed in the registry: Chiesi SAS · First submitted after Chiesi SAS became part of Chiesi Farmaceutici S.p.A.
- Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes RegistryActive, not recruitingNCT04076813
Sponsor listed in the registry: Chiesi USA, Inc. · First submitted after Chiesi USA, Inc. became part of Chiesi Farmaceutici S.p.A.